Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EvommuneEVMN -0.63%10 OCF Margin % is 0.00% as of Jun. 2026. GuruFocus rates EVMN with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 954 Biotechnology companies, Evommune ranks worse than 77.88% on this metric.
The historical data trend for Evommune's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Evommune's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evommune OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Evommune's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Evommune's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evommune (EVMN) has a OCF Margin % of 0.00% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Evommune and its competitors. According to the industry distribution chart, Evommune ranks #743 out of 954 companies in the Biotechnology industry, placing it in the top 77.9%.
Is Evommune's OCF Margin % too high?
Evommune's current OCF Margin % is 0.00%. Based on the distribution chart, Evommune ranks #743 out of 954 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Evommune has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Evommune's OCF Margin % compare to OCGN and PBYI?
According to the Biotechnology industry distribution chart, Evommune ranks #743 out of 954 companies for OCF Margin %. This places Evommune in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Evommune and its competitors. Evommune's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evommune stock overvalued right now?
Evommune (EVMN) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Evommune's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Evommune (EVMN), the current OCF Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
10GF Score
Get the complete analysis for EVMN
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVMN has been successfully added to your 
